Levetiracetam
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Levetiracetam: From Epilepsy to Visual Epilepsy
One-Sentence Summary
Levetiracetam is an established second-generation antiseizure medication, long used in the management of epilepsy (partial-onset and generalised seizures). The TxGNN model predicts potential efficacy in Visual Epilepsy, a rare photosensitive/reflex epilepsy subtype, with 9 clinical trials and 20 publications currently associated with this prediction — though most of this evidence comes from general epilepsy or traumatic-brain-injury seizure-prevention studies rather than trials specific to visual epilepsy itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Epilepsy (partial-onset and generalised seizures) — no structured UK licensing text was returned in this evidence pack |
| Predicted New Indication | Visual epilepsy |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L4 |
| UK Market Status | Not marketed (per this evidence pack) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data is not available in this evidence pack. Based on general clinical knowledge, levetiracetam is a broad-spectrum antiseizure medication that binds synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and dampening abnormal, hypersynchronous neuronal firing. Its efficacy across multiple epilepsy phenotypes is well established in clinical practice.
Visual epilepsy is considered a subtype of reflex epilepsy, in which seizures are triggered by visual stimuli (e.g. flickering light, patterns) via cortical hyperexcitability — mechanistically a plausible extension of levetiracetam’s established antiseizure activity, since reflex/stimulus-triggered seizures share the same underlying cortical excitability pathophysiology as the seizure types levetiracetam is already used to treat.
However, the supporting evidence collected for this candidate is largely indirect: the clinical trials and literature identified relate mainly to general epilepsy management, traumatic brain injury seizure prophylaxis, and psychiatric hippocampal hyperexcitability, rather than to visual/photosensitive epilepsy specifically. No trial in this pack directly enrols or reports outcomes for a visual-epilepsy-defined population, so the mechanistic rationale currently outpaces the direct clinical evidence.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT04573803 | Phase 3 | Not yet recruiting | 1,649 | MAST trial: comparing duration and choice (phenytoin vs levetiracetam) of antiepileptic therapy for seizure prevention after traumatic brain injury |
| NCT00855738 | Phase 4 | Completed | 111 | Liceo study: observational assessment of newer AEDs, including levetiracetam, as first-choice bitherapy in focal epilepsy |
| NCT07336992 | Phase 3 | Not yet recruiting | 580 | RCT evaluating prophylactic levetiracetam for functional outcome in acute intracerebral haemorrhage |
| NCT03107507 | Phase 4 | Unknown | 40 | Efficacy of levetiracetam in controlling neonatal seizures |
| NCT04833907 | Phase 1/2 | Enrolling by invitation | 24 | Gene-therapy trial for Canavan disease; levetiracetam relevance is tangential |
| NCT00105040 | Phase 2 | Completed | 87 | Placebo-controlled safety study of cognitive/neuropsychological effects of adjunctive levetiracetam in children with refractory partial-onset seizures |
| NCT04559529 | Phase 2 | Completed | 62 | Levetiracetam’s effect on hippocampal hyperactivity in psychosis, assessed via a visual scene-processing fMRI task |
| NCT04277936 | Phase 2 | Terminated | 1 | Same hippocampal hyperactivity/psychosis design as above; terminated early |
| NCT00203216 | N/A | Completed | 31 | Open-label trial of levetiracetam for migraine prophylaxis, with or without visual aura |
Note: None of the above trials specifically enrol a visual-epilepsy-defined population; relevance is mechanistic/general-epilepsy rather than disease-specific.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35963261 | 2022 | Phase 3 RCT | The Lancet Neurology | PEACH trial: prophylactic levetiracetam in acute intracerebral haemorrhage — did not clearly reduce acute seizure risk |
| 34286461 | 2022 | Systematic Review/Meta-analysis | Neurocritical Care | Levetiracetam commonly used for seizure prophylaxis in ICH/TBI/SAH; optimal dosing and efficacy remain unclear |
| 32385134 | 2020 | RCT | Pediatrics | Levetiracetam vs phenobarbital for neonatal seizures |
| 37378757 | 2023 | Systematic Review/Network Meta-analysis | Journal of Neurology | Comparative efficacy/safety of antiseizure medications, including levetiracetam, for idiopathic generalised epilepsies |
| 40450767 | 2025 | Systematic Review/Meta-analysis | Epilepsy & Behavior | Levetiracetam efficacy for myoclonic seizures in idiopathic generalised epilepsy (incl. JME) |
| 38316735 | 2024 | Clinical Practice Guideline | Neurocritical Care | Guideline on seizure prophylaxis in adults hospitalised with moderate-severe TBI |
| 36209676 | 2022 | Systematic Review/Network Meta-analysis | Seizure | Treatment options for benzodiazepine-resistant status epilepticus |
| 35976303 | 2022 | Review | Arquivos de Neuro-Psiquiatria | Review of diagnosis, monitoring and treatment of status epilepticus |
| 21936590 | 2011 | Review | CNS Drugs | “Spotlight on levetiracetam in epilepsy” — overview of approved indications and clinical use |
| 38678766 | 2024 | RCT | Seizure | Phenytoin vs levetiracetam for acute symptomatic seizures in children with acute encephalitis syndrome |
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(No structured warnings, contraindications, or DDI data were returned for levetiracetam in this evidence pack — the accompanying data-gap log flags TFDA/MHRA labelling warnings as a blocking gap for safety assessment.)
Conclusion and Next Steps
Decision: Hold
Rationale: The specific evidence for visual epilepsy is indirect — it consists mainly of general epilepsy, TBI-seizure-prophylaxis, and psychiatric hippocampal-excitability studies rather than trials in a visual-epilepsy-defined population, corresponding to L4 evidence (mechanism/preclinical-level). No UK marketing authorisation data or SmPC safety information could be located, which further limits readiness for clinical evaluation.
Worth noting: Within this same evidence pack, a related candidate — status epilepticus (rank 9, score 99.91%) — shows substantially stronger evidence (L1, multiple completed Phase 3 RCTs including the NEJM-published ESETT trial), with a “Proceed with Guardrails” recommendation. This may warrant separate, prioritised evaluation ahead of visual epilepsy.
To proceed, the following is needed:
- Disease-specific clinical evidence (trials or case series) directly evaluating levetiracetam in visually-triggered/photosensitive reflex epilepsy
- TFDA/MHRA SmPC warnings, contraindications and interaction data (currently a blocking data gap)
- Confirmed mechanism-of-action documentation (currently a data gap)
- Confirmation of UK marketing authorisation status, as none is currently on record in this evidence pack
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.